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1. INTRODUCTION {#dom13515-sec-0001}
===============

Basal insulin is an essential component of the management strategy for individuals with type 2 diabetes (T2DM),[1](#dom13515-bib-0001){ref-type="ref"} and is often required when lifestyle interventions and non‐insulin glucose‐lowering agents fail to achieve target glycaemic control. However, basal insulin treatment is often delayed, and/or dose titration is not optimized, resulting in poor glucose control despite initiation of insulin. Studies have identified fear of hypoglycaemia as one of the dominant reasons for suboptimal use of basal insulin.[2](#dom13515-bib-0002){ref-type="ref"} Hypoglycaemic events often occur at night, when warning symptoms are physiologically blunted, and may result in both acute and long‐term clinical consequences.[3](#dom13515-bib-0003){ref-type="ref"} As such, these nocturnal events elicit fear, in both the individuals with T2DM and the healthcare practitioners. Long‐acting basal insulin analogues have been developed to deliver constant and predictable glucose‐lowering effects over 24 hours, providing improved glycaemic control and reduced risk of nocturnal hypoglycaemia because of a rather flat pharmacodynamic (PD) profile.[4](#dom13515-bib-0004){ref-type="ref"}

Insulin glargine 300 U/mL (Gla‐300) has more stable and prolonged pharmacokinetic (PK) and PD profiles than insulin glargine 100 U/mL (Gla‐100).[5](#dom13515-bib-0005){ref-type="ref"} The EDITION treat‐to‐target clinical trials showed that the improved PK and PD properties of Gla‐300 translate into clinical benefits such as glycaemic control equivalent to that of Gla‐100 with less hypoglycaemia in individuals with T2DM, primarily, but not exclusively, at night (defined as 0:00--05:59 [am]{.smallcaps}).[6](#dom13515-bib-0006){ref-type="ref"}, [7](#dom13515-bib-0007){ref-type="ref"}, [8](#dom13515-bib-0008){ref-type="ref"}

The value of extending time intervals beyond 00:00--5:59 [am]{.smallcaps} when assessing nocturnal hypoglycaemia has been shown in a patient‐level meta‐analysis of the global EDITION trials in T2DM (EDITION 1, 2 and 3), in which a clinically defined window from 10:00 [pm]{.smallcaps} to the time of pre‐breakfast self‐monitored plasma glucose (SMPG) measurement (median, 7:30 [am]{.smallcaps}) resulted in the inclusion of many more hypoglycaemic events compared to the predefined 0:00--5:59 [am]{.smallcaps} window, and confirmed a clinically relevant reduction in the risk of hypoglycaemia with Gla‐300 during the overnight fasting period.[9](#dom13515-bib-0009){ref-type="ref"} However, the EDITION 1 trial[7](#dom13515-bib-0007){ref-type="ref"} examined individuals using prandial insulin in addition to basal insulin; thus, the results may not be specifically attributed to basal insulin alone.

The present *post‐hoc* analysis was designed to evaluate the risk of nocturnal hypoglycaemia with Gla‐300 vs Gla‐100 by using data pooled from three trials in which participants with T2DM used only basal insulin (EDITION 2, 3 and JP 2) without the confounding effects of the prandial insulin used in EDITION 1. Hypoglycaemia at night was analysed using the predefined 0:00--5:59 [am]{.smallcaps} nocturnal interval and three expansions thereof.

2. METHODS {#dom13515-sec-0002}
==========

2.1. Trial design {#dom13515-sec-0003}
-----------------

EDITION 2, EDITION 3 and EDITION JP 2 were multicentre, randomized, open‐label, two‐arm, parallel‐group, phase 3a studies in different populations of adults with T2DM (NCT01499095, NCT01676220, NCT01689142) and have been described previously.[6](#dom13515-bib-0006){ref-type="ref"}, [8](#dom13515-bib-0008){ref-type="ref"}, [10](#dom13515-bib-0010){ref-type="ref"} In EDITION 2 and EDITION JP 2, participants must have used basal insulin treatment (≥ 42 U/d in EDITION 2) for more than 6 months, in combination with non‐insulin antihyperglycaemic agents within the previous 4 weeks. For the EDITION 2 trial, exclusion criteria included recent (within the past 2 months) use of sulphonylureas. In the EDITION JP 2 trial, concomitant sulphonylurea and/or glinide treatment was permitted, with doses adjusted if at least two symptomatic or at least one severe hypoglycaemic episode(s) occurred. Overall, 63% of participants in the EDITION JP 2 trial received sulphonylureas and/or glinides, with a similar proportion of participants in the Gla‐300 (62%) and Gla‐100 (64%) groups.[11](#dom13515-bib-0011){ref-type="ref"} Participants in the EDITION 3 trial were insulin‐naïve and were required to have used non‐insulin antihyperglycaemic agents for at least 6 months before screening; if participants were receiving sulphonylureas/glinides, these medications were discontinued.

Participants were randomized (1:1) to receive once‐daily injections of Gla‐300 (Toujeo, Sanofi, Paris, France) using a modified SoloSTAR (Sanofi) pen‐injector in the EDITION 2 trial or a modified Tactipen (Sanofi) injector in the EDITION 3 and JP 2 trials, or Gla‐100 (Lantus, Sanofi) using a SoloSTAR pen. Basal insulin was titrated, seeking a pre‐breakfast SMPG target of 4.4--5.6 mmol/L (80--100 mg/dL).

Basal insulin injections were to be administered in the evening, defined as the time immediately before the evening meal until bedtime, at the same time every day. All participants recorded time of injection.

2.2. Outcomes {#dom13515-sec-0004}
-------------

Pre‐specified hypoglycaemia endpoints, categorized according to American Diabetes Association definitions,[12](#dom13515-bib-0012){ref-type="ref"} were the same for all studies and have been reported previously.[6](#dom13515-bib-0006){ref-type="ref"}, [8](#dom13515-bib-0008){ref-type="ref"}, [10](#dom13515-bib-0010){ref-type="ref"} Confirmed or severe hypoglycaemia was defined as any event that was documented and symptomatic, was asymptomatic with a plasma glucose measurement of ≤3.9 mmol/L (≤70 mg/dL) or was severe. Hypoglycaemic events with more stringent plasma glucose measurements of \<3.0 mmol/L (\<54 mg/dL) were also analysed. During the main 6‐month treatment period, hypoglycaemic events were reported by time of day, as percentage of participants with at least one event and as annualized rates (events per participant‐year).

2.3. Definitions of nocturnal hypoglycaemia {#dom13515-sec-0005}
-------------------------------------------

Four windows were used for evaluation of nocturnal hypoglycaemia:Predefined window as per study protocol, with events occurring between 0:00--5:59 [am]{.smallcaps} classified as nocturnal.Expansion of predefined window by 2 hours in the evening (10:00 [pm]{.smallcaps}--5:59 [am]{.smallcaps}).Expansion of predefined window by 2 hours in the morning (0:00--7:59 [am]{.smallcaps}).Individualized final window, defined by a fixed start time and an end time that varied by participant (10:00 [pm]{.smallcaps} to each individual\'s recorded time of pre‐breakfast SMPG).

2.4. Data analysis {#dom13515-sec-0006}
------------------

While the EDITION 2, 3 and JP 2 trials were conducted in different populations, all three trials had a similar design, and the consistent study designs and endpoints allowed a pooled analysis. Hypoglycaemia over 6 months was assessed in safety populations by analysing patient‐level data pooled from the EDITION 2, 3 and JP 2 trials. Point estimates for the relative risk and 95% confidence intervals (CIs) for the percentage of participants with at least one hypoglycaemic event were estimated using the Cochran--Mantel--Haenszel method, while rates of hypoglycaemia (events per participant‐year) were analysed using an over‐dispersed Poisson regression model to determine rate ratios and 95% CIs.

3. RESULTS {#dom13515-sec-0007}
==========

Baseline characteristics (Table [S1](#dom13515-supitem-0001){ref-type="supplementary-material"}) were, in general, similar between the trials, with the exception of BMI, which was lower in the EDITION JP 2 trial (mean \[SD\]: Gla‐300, 25.7 \[4.0\]; Gla‐100, 24.8 \[3.6\] kg/m^2^) than in the EDITION 2 trial (mean \[SD\]: Gla‐300, 34.8 \[6.6\]; Gla‐100, 34.8 \[6.1\] kg/m^2^) and the EDITION 3 trial (mean \[SD\]: Gla‐300, 32.8 \[6.9\]; Gla‐100, 33.2 \[6.6\] kg/m^2^). Distribution, by time of day, of the time of the pre‐breakfast SMPG and basal insulin injection was comparable for the Gla‐300 and Gla‐100 groups and between studies (Figure [S1](#dom13515-supitem-0001){ref-type="supplementary-material"}). For the pooled analysis, the overall median time of pre‐breakfast SMPG was 7:30 [am]{.smallcaps} (interquartile range \[IQR\]: 6:55--8:16 [am]{.smallcaps}) and the median time of basal insulin injection was 9:17 [pm]{.smallcaps} (IQR: 8:00--10:05 [pm]{.smallcaps}).

At every time point analysed, fewer participants reported confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemia with Gla‐300 than with Gla‐100 (Figure [1](#dom13515-fig-0001){ref-type="fig"}A). This finding was consistent with those of the individual EDITION 2, 3 and JP 2 trials, in which, for the majority of time points, fewer participants reported confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemia with Gla‐300 than with Gla‐100 (Figure [S2](#dom13515-supitem-0001){ref-type="supplementary-material"}). For confirmed (\<3.0 mmol/L \[\<54 mg/dL\]) or severe hypoglycaemia (Figure [1](#dom13515-fig-0001){ref-type="fig"}B) a similar pattern was observed. A greater percentage of 24‐hour events were defined as nocturnal when using windows that extended past 6:00 [am]{.smallcaps} (Table [1](#dom13515-tbl-0001){ref-type="table"}).

![Percentage of participants with at least one confirmed or severe hypoglycaemic event at both the (A) ≤ 3.9 mmol/L (≤70 mg/dL) threshold and the (B) \< 3.0 mmol/L (\<54 mg/dL) threshold (safety population^†^) -- Pool of results from the EDITION 2, EDITION 3 and EDITION JP 2 trials. ^†^Gla‐300 N = 958, Gla‐100 N = 964.\
Abbreviation SMPG, self‐monitored plasma glucose](DOM-21-402-g001){#dom13515-fig-0001}

###### 

Nocturnal hypoglycaemia by window (safety population) -- Pool of results from the EDITION 2, EDITION 3 and EDITION JP 2 trials

  Nocturnal window                                       0:00--5:59 [am]{.smallcaps} (predefined window in EDITION studies)   10:00 [pm]{.smallcaps}--5:59 [am]{.smallcaps}   0:00--7:59 [am]{.smallcaps}   10:00 [pm]{.smallcaps} to pre‐breakfast SMPG                                                    
  ------------------------------------------------------ -------------------------------------------------------------------- ----------------------------------------------- ----------------------------- ---------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------
  Confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe                                                                                                                                                                                                                                                           
  Participants with ≥1 hypoglycaemic event (%)           23.6                                                                 33.2                                            9.6                           28.6                                           36.6   8.0    40.9   52.4   11.5   44.9   57.1   12.2
  Total number of events                                 754                                                                  1275                                            521                           925                                            1412   487    2173   3132   959    2260   3210   950
  Events per participant, y                              1.7                                                                  2.8                                             1.1                           2.1                                            3.1    1.0    4.8    6.9    2.1    5.0    7.1    2.1
  Percentage of events in 24 h defined as nocturnal      16.4                                                                 20.6                                            4.2                           20.2                                           22.8   2.6    47.4   50.7   3.3    49.3   51.9   2.6
  Confirmed (\<3.0 mmol/L \[\<54 mg/dL\]) or severe                                                                                                                                                                                                                                                         
  Participants with ≥1 hypoglycaemic event (%)           7.2                                                                  10.0                                            2.8                           8.6                                            11.7   3.1    10.4   14.7   4.3    12.2   17.0   4.8
  Total number of events                                 112                                                                  191                                             79                            140                                            214    74     209    317    108    251    357    106
  Events per participant, y                              0.3                                                                  0.4                                             0.1                           0.3                                            0.5    0.2    0.5    0.7    0.2    0.6    0.8    0.2
  Percentage of events in 24 h defined as nocturnal      26.0                                                                 34.2                                            8.2                           32.6                                           38.4   5.8    48.6   56.8   8.2    58.4   64.0   5.6
  Documented symptomatic (≤ 3.9 mmol/L \[≤ 70 mg/dL\])                                                                                                                                                                                                                                                      
  Participants with ≥ hypoglycaemic event (%)            17.1                                                                 23.4                                            6.3                           19.9                                           25.7   5.8    26.4   33.1   6.7    29.3   35.9   6.6
  Total number of events                                 468                                                                  721                                             253                           529                                            782    253    1029   1351   322    1075   1445   370
  Events per participant, y                              1.0                                                                  1.6                                             0.6                           1.2                                            1.7    0.5    2.3    3.0    0.7    2.4    3.2    0.8
  Percentage of events in 24 h defined as nocturnal      23.1                                                                 28.1                                            5.0                           26.2                                           30.4   4.2    50.9   52.6   1.7    53.2   56.2   3.0
  Documented symptomatic (\<3.0 mmol/L \[\<54 mg/dL\])                                                                                                                                                                                                                                                      
  Participants with ≥1 hypoglycaemic event (%)           5.8                                                                  8.6                                             2.8                           6.8                                            9.6    2.8    8.2    11.4   3.2    9.6    13.2   3.6
  Total number of events                                 83                                                                   162                                             79                            100                                            177    77     138    239    101    178    272    94
  Events per participant, y                              0.2                                                                  0.4                                             0.2                           0.2                                            0.4    0.2    0.3    0.5    0.2    0.4    0.6    0.3
  Percentage of events in 24 h defined as nocturnal      28.8                                                                 41.4                                            12.6                          34.7                                           45.3   10.6   47.9   61.1   13.2   61.8   69.6   7.8

Abbreviation: SMPG, self‐monitored plasma glucose.

Difference, Gla‐100 minus Gla‐300 (please also see Figures [S3](#dom13515-supitem-0001){ref-type="supplementary-material"} and [S4](#dom13515-supitem-0001){ref-type="supplementary-material"} for results of specific analysis of the differences between Gla‐300 and Gla‐100, including relative risk, rate ratios and associated confidence intervals).

Percentage of participants with ≥ one confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemic event almost doubled when using nocturnal window definitions that extended past 5:59 [am]{.smallcaps} (0:00--7:59 [am]{.smallcaps} and 10:00 [pm]{.smallcaps} to pre‐breakfast SMPG) vs the predefined window (0:00--5:59 [am]{.smallcaps}) (Table [1](#dom13515-tbl-0001){ref-type="table"}). This was consistent with results from the individual EDITION trials ([S2](#dom13515-supitem-0001){ref-type="supplementary-material"}). The risk of at least one confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe event was consistently lower with Gla‐300 than with Gla‐100, regardless of the nocturnal window used (Figure [S3](#dom13515-supitem-0001){ref-type="supplementary-material"}). Approximately two to three times more hypoglycaemic events were identified during nocturnal windows that extended past 5:59 [am]{.smallcaps} vs the predefined window in the pooled analyses (Table [1](#dom13515-tbl-0001){ref-type="table"}), consistent with results from the individual EDITION 2, 3 and JP 2 trials (Table [S2](#dom13515-supitem-0001){ref-type="supplementary-material"}). Annualized rates of hypoglycaemia also increased approximately two‐fold when using extended nocturnal windows, for all definitions of hypoglycaemia (Table [1](#dom13515-tbl-0001){ref-type="table"} and [S4](#dom13515-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#dom13515-sec-0008}
=============

The aim of this *post‐hoc* study was to more fully explore the 24‐hour time course and the clinical significance of hypoglycaemic events occurring during treatment of T2DM with basal insulin only by comparing the risk of hypoglycaemia during the predefined nocturnal window commonly used in clinical trials with expanded windows.

This analysis of pooled, patient‐level data from the EDITION 2, 3 and JP 2 studies demonstrates that the incidence of reported hypoglycaemia with both Gla‐300 and Gla‐100 was highest during the 6:00--8:00 [am]{.smallcaps} interval, outside the standard, predefined 0:00--5:59 [am]{.smallcaps} window. The number of hypoglycaemic events reported was more than doubled by including this 2‐hour period, suggesting that a window incorporating this time interval is of clinical relevance when examining the role of basal insulin. The pattern of findings from pooled data was also seen in the individual EDITION studies. The high number of events during the 6:00--8:00 [am]{.smallcaps} interval may be related to the protocol‐mandated measurement of pre‐breakfast SMPG, but the fact that this interval, which is approximately 8--11 hours after basal insulin injection, near dawn and often before the first meal of the day, includes more events is compatible with the pharmacodynamics of basal insulin in T2DM during nocturnal fasting.[13](#dom13515-bib-0013){ref-type="ref"} In clinical reality, up‐titration of basal insulin would increase the dose until the dawn phenomenon was overcome, and euglycaemia would ideally be achieved without risk of hypoglycaemia.

Lower risk of hypoglycaemia with Gla‐300 vs Gla‐100 extends past the predefined nocturnal window (0:00--5:59 [am]{.smallcaps}), in line with the flatter and more evenly distributed PK and PD profiles of Gla‐300 compared with Gla‐100. The observation in the present study of a higher risk of hypoglycaemia during waking hours may not inspire the fear of events that occur during sleep; however, these events are still important and clinically relevant, and efforts should be made to minimize the frequency of their occurrence.

Recently, a comparable analysis using pooled data from three trials of Gla‐300 (EDITION 1, 2 and 3) in T2DM was reported,[9](#dom13515-bib-0009){ref-type="ref"} with results similar to those presented here, including the finding that, while the relative risk and rate ratios move closer to 1.00 with the extended intervals, the conclusion of a reduced risk of hypoglycaemia with Gla‐300 vs Gla‐100 remains. However, only the present study indicates that the peak of hypoglycaemia incidence at 6:00--8:00 [am]{.smallcaps} is specifically the result of basal insulin, as, in the previous study,[9](#dom13515-bib-0009){ref-type="ref"} the prandial insulin at breakfast in the EDITION 1 trial might have confounded the risk of hypoglycaemia occurring almost 12 hours after evening injection of Gla‐300 or Gla‐100. Together, the previous study[9](#dom13515-bib-0009){ref-type="ref"} and the current, more specific, analysis provide strong evidence that evening injections of basal insulin confer the greatest risk of hypoglycaemia during the 6:00--8:00 [am]{.smallcaps} time interval.

Interestingly, the results observed in the EDITION JP 2 trial, which investigated Japanese participants, were similar to those observed in the EDITION 2 and 3 trials, which investigated Western populations, despite lower BMI and lower doses of insulin in the EDITION JP 2 trial. In theory, the use of sulphonylureas and/or glinides in the EDITION JP 2 trial might have confounded the results of the present pooled analysis, as sulphonylureas increase the risk of hypoglycaemia[11](#dom13515-bib-0011){ref-type="ref"} and were not allowed in the EDITION 2 and 3 trials.[6](#dom13515-bib-0006){ref-type="ref"}, [8](#dom13515-bib-0008){ref-type="ref"} However, such confounding seems unlikely because a similar percentage of participants using sulphonylureas and/or glinides were allocated to the Gla‐300 and Gla‐100 groups in the EDITION JP 2 trial,[11](#dom13515-bib-0011){ref-type="ref"} and because the 24‐hour distribution of hypoglycaemia in the EDITION JP 2 trial was similar to that seen in the EDITION 2 and 3 trials. Thus, inclusion of the EDITION JP 2 trial, which is representative of an Asian population, enriches and strengthens the present pooled analysis of the 24‐hour distribution of hypoglycaemia.

A similar study analysing rates of nocturnal hypoglycaemia with insulin degludec vs Gla‐100 also demonstrated that adding 2 hours to the conventional, predefined 0:00--5:59 [am]{.smallcaps} nocturnal window resulted in a two‐ to three‐fold increase, with both insulins, in the number of hypoglycaemic episodes per 100 patient‐years of exposure.[14](#dom13515-bib-0014){ref-type="ref"}

These results highlight contrasts between nocturnal hypoglycaemia, as defined for regulatory submission, and wider definitions which appear to be of more clinical relevance. Use of a wider window may be particularly relevant in examining the risk of hypoglycaemia that is specifically the result of basal insulin in individuals with diabetes, especially in those with a higher risk of hypoglycaemia. In the recently published clinical trial of Gla‐300 vs Gla‐100 in older individuals with T2DM, the SENIOR study,[15](#dom13515-bib-0015){ref-type="ref"} intervals of 10:00 [pm]{.smallcaps}--8:59 [am]{.smallcaps} and 0:00--5:59 [am]{.smallcaps} were both used to categorize nocturnal hypoglycaemia,[16](#dom13515-bib-0016){ref-type="ref"} although only data for the latter interval were reported.[15](#dom13515-bib-0015){ref-type="ref"}

Limitations of the present study include the potential under‐reporting of nocturnal events that do not awaken the individual. Use of continuous glucose monitoring devices for future studies would provide a more accurate description of the number and timing of hypoglycaemic events. In addition, the pooled analyses presented here were not pre‐specified. However, the EDITION studies were designed from the outset with consistent study designs and endpoints that allowed analysis of pooled data.

In conclusion, this study has demonstrated that hypoglycaemic events that are specifically induced by basal insulin are most frequently reported between 6:00 and 8:00 [am]{.smallcaps}, with the time of breakfast being varied, but most often between 7:00 and 8:00 [am]{.smallcaps}. Broader windows of observation for hypoglycaemia during a nocturnal/fasting period that extends beyond 6:00 [am]{.smallcaps} allow identification of more affected individuals and more events induced by basal insulin. It would be useful if future studies comparing basal insulins could report results of hypoglycaemic events that occurred within this wider window as well as the predefined window. The lower incidence and rate of nocturnal hypoglycaemia with Gla‐300 vs Gla‐100 was confirmed using all analysed time windows, showing a consistently reduced risk with Gla‐300 compared to Gla‐100.
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**Table S1.** Summary of baseline characteristics of the pool of EDITION 2, EDITION 3 and EDITION JP 2 (randomised population).

**Table S2.** Nocturnal confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemia by window (safety population) -- individual EDITION 2, EDITION 3 and EDITION JP 2 studies.

**Figure S1.** Distribution by time of day of the median time of participants pre‐breakfast SMPG and basal insulin injection (safety population^†^) -- individual EDITION 2, EDITION 3 and EDITION JP 2 studies and pool of EDITION 2, EDITION 3 and EDITION JP 2.

**Figure S2.** Distribution by time of day of the percentage of participants with ≥1 confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemic event -- individual EDITION 2, EDITION 3 and EDITION JP 2 studies (safety population^†^).

**Figure S3.** Relative risk of ≥1 hypoglycaemic event by nocturnal window during the 6‐month treatment period (safety population^†^) -- pool of EDITION 2, EDITION 3 and EDITION JP 2.

**Figure S4.** Rate ratios of hypoglycaemia by nocturnal window during the 6‐month treatment period (safety population^†^) -- pool of EDITION 2, EDITION 3 and EDITION JP 2.
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